New strategies in advanced cervical cancer: From angiogenesis blockade to immunotherapy

Clinical Cancer Research

Volumn 20, Issue 21, 2014, Pages 5349-5358

  Tewari, Krishnansu S ^a   Monk, Bradley J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRIVANIB; CISPLATIN; LIVE VACCINE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MK 1775; NOTCH RECEPTOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SUNITINIB; TEMSIROLIMUS; TOPOTECAN; UNCLASSIFIED DRUG; VASCULOTROPIN; WART VIRUS VACCINE; CAPSID PROTEIN; HPV L1 PROTEIN, HUMAN PAPILLOMAVIRUS; ONCOPROTEIN;

ANTIANGIOGENIC THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DNA METHYLATION; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; EGFR GENE; GENE EXPRESSION; GENE FUNCTION; HPV E6 GENE; HPV E7 GENE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; ONCOGENE; ONCOGENE K RAS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PIK3CA GENE; REVIEW; SOMATIC MUTATION; UTERINE CERVIX CANCER; VIRUS GENE; ANIMAL; FEMALE; GENETICS; HUMAN PAPILLOMAVIRUS DNA TEST; IMMUNOTHERAPY; NEOVASCULARIZATION, PATHOLOGIC; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROCEDURES; TUMOR RECURRENCE; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ANIMALS; CAPSID PROTEINS; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; IMMUNOTHERAPY; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84910028030     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1099     Document Type: Review

References (71)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
3. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Karmer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014;64:252-71.
4. Tewari KS, Monk BJ. Invasive cervical cancer. In:DiSaia PJ, Creasman WT, eds. Clinical gynecologic oncology. 8th ed. Philadelphia: Mosby, 2012.
5. Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 1941;42:193.
6. Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 1983;80:3812-5.
7. Frazer IH. Development and implementation of papillomavirus prophylactic vaccines. J Immunol 2014;192:4007-11.
8. Dochez C, Bogers JJ, Verhelst R, Rees H. HPV vaccines to prevent cervicalcancer andgenitalwarts: an update. Vaccine 2014;32:1595-601.
9. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56:1-24.
10. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59:626-9.
11. Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1705-8.
12. Joura E, on behalf of the V503-001 study team. Efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16-to 26-year old women. EUROGIN 2013;8-4.
13. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American cancer society, American society for colposcopy and cervical pathology, and American society for clinical pathology screening guidelines for the prevention and detection of cervical cancer. Am J Clin Pathol 2012;137:516-42.
14. Mover VAU.S. Preventive Services Task Force. Screening for cervical cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2012;156:880-91.
15. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013;17:S1-S27.
16. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011;12:880-90.
17. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obsstet 2009;105:107-8.
18. Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol 2007;25:2952-65.
19. Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, van Hummelen P, et al. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 2013;119:3776-83.
20. Ojesina AI, Lichtenstein L, Freeman SS, Pedamullu CS, Imaz-Rosshandler I, Pugh TJ, et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014;506:371-5.
21. Munoz N, Bosch X, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classifi cation of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
22. Marongui L, Godi A, Parry JV, Beddows S. Human papillomavirus 16, 18, 31 and 5 viral load, integration and methylation status stratified by cervical disease stage. BMC Cancer 2014;14:384.
23. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59.
24. Hansel A, Steinbach D, Greinke C, Schmitz M, Eiselt J, Scheungraber C, et al. A promising DNA methylation signature for the triage of high-risk human papillomavirus DNA-positive women. PLoS One 2014;9:e91905.
25. Vasiljevic N, Scibior-Bentkowska D, Brentnall AR, Cuzick J, Lorincz AT. Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women. Gynecol Oncol 2014;132:709-14.
26. Mir S. Investigating human papillomavirus 16 methylation as a biomarker for high-grade cervical intraepithelial neoplasia. Obstet Gynecol 2014;123(Suppl 1):184S-5S.
27. Verhoef VM, Bosgraaf RP, van Kemenade FJ, Rozendaal L, Heidman DA, Hesselink AT, et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): A ransomised controlled non-inferiority trial. Lancet Oncol 2014;15:315-22.
28. Melsheimer P, Vinokurova S, Wentzensen N, Bastert G, von Knebel Doeberitz M. DNA aneuploidy and integration of human papillomavirus type 16 E6/E7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. Clin Cancer Res 2004;10:3059-63.
29. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-34.
30. Habbous S, Pang V, Eng L, Xu W, Kurtz G, Liu FF, et al. p53Arg72Pro polymorphism, HPV status and initiation, progression, and development of cervical cancer: a systematic review and meta-analysis. Clin Cancer Res 2012;18:6407-15.
31. Zanier K, Charbonnier S, Sidi AO, McEwen AG, Ferrario MG, Poussin-Courmontagne P, et al. Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. Science 2013;339:694-8.
32. Schwarz JK, Payton JE, Rashmi R, Xiang T, Jia Y, Huettner P, et al. Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res 2012;18:1464-71.
33. Molinolo AA, Marsh C, El Dinali M, Gangane N, Jennison K, Hewitt K, et al. mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas. Clin Cancer Res 2012;18:2558-68.
34. Zagouras P, Sifani S, Blaumueller CM, Carcanqui ML, Artavanis-Tsakonas S. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc Natl Acad Sci USA 1995;92:6414-8.
35. Tewari KS, Taylor JA, Liao SY, DiSaia PJ, Burger RA, Monk BJ, et al. Development and assessment of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model. Gynecol Oncol 2000;77:137-48.
36. Tripathi R, Rath G, Jawanjal P, Sharma S, Singhal P, Bhambhani S, et al. Clinical impact of de-regulated Notch-1 and Notch-3 in the development and progression of HPV-associated different histological subtypes of precancerous and cancerous lesions of human uterine cervix. PLoS One 2014;9:e98642.
37. Srivastava S, Ramdass B, Nagarajan S, Rehman M, Mukherjee G, Krishna S. Notch 1 regulates the functional contribution of RhoC to cervical carcinoma progression. Br J Cancer 2010;102:196-205.
38. Dellas A, Moch H, Schultheiss E, Feichter G, Almendral AC, Gudat F, et al. Angiogenesis in cervical neoplasia: microvessel quantification in precancerous lesions and invasive carcinomas with clinicopathologic correlations. Gynecol Oncol 1997;67:27-33.
39. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl) 1999;77:527-43.
40. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
41. Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996;56:4032-9.
42. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74.
43. Choi KS, Bae MK, Jeong JW, Moon HE, Kim KW. Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol 2003;36:120-7.
44. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2009;27:1069-74.
45. Deligeouroglou E, Giannouli A, Athanasopoulos N, Karountzos V, Vatopoulou A, Dimopoulos K, et al. HPV infection: immunological aspects and their utility in future therapy. Infect Dis Obstet Gynecol 2013;2013:540850.
46. Karim R, Jordanova ES, Piersma SJ, Kenter GG, Chen L, Boer JM, et al. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patientswith cervical carcinoma. Clin Cancer Res 2009;15:6341-7.
47. Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010;28:3562-9.
48. Tewari KS, Sill MW, Long HJIII, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370:734-43.
49. Eskander RN, Tewari KS. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer. Curr Opin Obstet Gynecol 2014;26:1-10.
50. NCI Press Release. Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer. Available from: www.cancer.gov/newscenter/newsfromnci/2013/GOG240.
51. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cervical Cancer Version 1.2014 NCCN.org.
52. Newcervical cancer drug added to Cancer Drugs Fund [cited 2014 Mar 6]. Available from: www.england.nhs.uk/2014/03/06/new-cervical-cancer-drug.
53. Monk BJ, Tewari KS. Evidence-based therapy for recurrent cervical cancer. J Clin Oncol 2014;32:2687-90.
54. Eskander RN, Tewari KS. Targeting angiogenesis in advanced cervical cancer. Ther Adv Med Oncol 2014. In press.
55. Jakobsson L, Bentley K, Gerhardt H. VEGFRs and Notch: a dynamic collaboration in vascular patterning. Biochem Soc Trans 2009;37:1233-6.
56. Benedito R, Rocha SF, Woeste M, Zamykal M, Radtke F, Casanovas O, et al. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signaling. Nature 2012;484:110-4.
57. Hernandez SL, Banerjee D, Garcia A, Kangsamaksin T, Cheng WY, Anastassiou D, et al. Notch and VEGF pathways play distinct but complementary roles in tumor angiogenesis. Vasc Cell 2013;5:17.
58. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012;30:777-82.
59. Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol 2010;117:473-6.
60. Tinker AV, Ellard S, Welch S, Moens F, Allo G, Tsao MS, et al. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecol Oncol 2013;180:269-74.
61. Eskander RN, Tewari KS. Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. J Gynecol Oncol 2014;25:1-11.
62. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerpershoek G, van Persijn van Meerten EL, et al. HPV 16 synthetic long peptide (JPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med 2013;11:88.
63. Su J-H, Wu A, Scotney E, Ma B, Monie A, Hung CF, et al. Immunotherapy for cervical cancer: research status and clinical potential. BioDrugs 2010;24:109-29.
64. Basu P, Mehta AO, Jain MM, Gupta S, Nagarkar RV, Kumar V, et al. ADXS11-001 immunotherapy targeting HPV-E7: final results from a phase 2 study in Indian women with recurrent cervical cancer. J Clin Oncol 2014;32:5s(suppl;abstr 5610).
65. Hinrichs CS, Stevanovic S, Draper L, Somerville R, Wunderlich J, Restifo NP, et al. HPV-targeted tumor-infiltrating lymphocytes for cervical cancer. J Clin Oncol 2014;32:5s(suppl;abstr LBA3008).
66. de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, et al. Human papilloimavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004;64:5449-55.
67. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-7.
68. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
69. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;355:2443-54.
70. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
71. Yang W, Song Y, Lu YL, Sun JZ, Wang HW. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. Immunology 2013;139:513-22.